Allogene Therapeutics, Inc.
US ˙ NasdaqGS ˙ US0197701065

Introduction

This page provides a comprehensive analysis of the known insider trading history of David D Chang. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate David D Chang has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:ALLO / Allogene Therapeutics, Inc. President and CEO, Director 5,276,569
US:KITE / Kite Pharma, Inc. EVP, R&D, Chief Medical Off. 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by David D Chang. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases ALLO / Allogene Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ALLO / Allogene Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2018-10-15 ALLO Chang David D 40,000 18.0000 40,000 18.0000 720,000 22 33.3000 612,000 85.00

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ALLO / Allogene Therapeutics, Inc. Insider Trades
Insider Sales ALLO / Allogene Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ALLO / Allogene Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2025-03-14 ALLO Chang David D 46,668 1.9600 46,668 1.9600 91,469 61 0.9528 -47,004 -51.39
2025-02-03 ALLO Chang David D 46,003 1.6800 46,003 1.6800 77,285
2022-03-15 ALLO Chang David D 23,648 7.6488 23,648 7.6488 180,879
2021-03-15 ALLO Chang David D 20,513 38.5741 20,513 38.5741 791,271
2020-03-16 ALLO Chang David D 18,710 19.2417 18,710 19.2417 360,012
2020-03-16 ALLO Chang David D 1,625 20.0634 1,625 20.0634 32,603

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ALLO / Allogene Therapeutics, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by David D Chang as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-03-18 2025-03-14 4 ALLO Allogene Therapeutics, Inc.
Common Stock
S - Sale -46,668 5,276,569 -0.88 1.96 -91,469 10,342,075
2025-02-05 2025-02-03 4 ALLO Allogene Therapeutics, Inc.
Common Stock
S - Sale -46,003 5,317,237 -0.86 1.68 -77,285 8,932,958
2025-01-28 2025-01-24 4 ALLO Allogene Therapeutics, Inc.
Common Stock
A - Award 552,174 5,363,240 11.48
2024-05-20 2024-05-16 4 ALLO Allogene Therapeutics, Inc.
Common Stock
A - Award 344,828 4,810,106 7.72 2.90 1,000,001 13,949,307
2024-03-18 2024-03-14 4 ALLO Allogene Therapeutics, Inc.
Common Stock
F - Taxes -53,393 4,465,278 -1.18 4.33 -231,192 19,334,654
2024-01-31 2024-01-25 4 ALLO Allogene Therapeutics, Inc.
Common Stock
A - Award 317,800 4,513,203 7.57
2023-03-24 2023-03-22 4 ALLO Allogene Therapeutics, Inc.
Common Stock
A - Award 1,924,464 4,193,911 84.80
2023-03-16 2023-03-14 4 ALLO Allogene Therapeutics, Inc.
Common Stock
F - Taxes -22,340 2,269,447 -0.97 5.56 -124,210 12,618,125
2022-03-25 2022-03-23 4 ALLO Allogene Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 2,195,512 2,195,512
2022-03-17 2022-03-15 4 ALLO Allogene Therapeutics, Inc.
Common Stock
S - Sale -23,648 2,289,652 -1.02 7.65 -180,879 17,513,090
2021-05-26 2021-05-24 4 ALLO Allogene Therapeutics, Inc.
Stock Option (Right to Buy)
M - Exercise -27,410 541,190 -4.82
2021-05-26 2021-05-24 4 ALLO Allogene Therapeutics, Inc.
Common Stock
M - Exercise 27,410 2,312,279 1.20 18.22 499,410 42,129,723
2021-04-02 2020-08-31 4/A ALLO Allogene Therapeutics, Inc.
Common Stock
G - Gift 205,778 856,044 31.65
2021-04-02 2020-08-31 4/A ALLO Allogene Therapeutics, Inc.
Common Stock
G - Gift 205,778 856,044 31.65
2021-03-30 2021-03-26 4 ALLO Allogene Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 298,836 298,836
2021-03-30 2021-03-26 4 ALLO Allogene Therapeutics, Inc.
Common Stock
A - Award 80,452 2,284,869 3.65
2021-03-17 2021-03-15 4 ALLO Allogene Therapeutics, Inc.
Common Stock
S - Sale -20,513 2,204,417 -0.92 38.57 -791,271 85,033,402
2020-04-28 2020-04-24 4 ALLO Allogene Therapeutics, Inc.
Common Stock
J - Other 9,187 2,224,101 0.41
2020-04-28 2020-04-24 4 ALLO Allogene Therapeutics, Inc.
Common Stock
J - Other X 9,198 1,201,108 0.77
2020-04-28 2020-03-18 4 ALLO Allogene Therapeutics, Inc.
Common Stock
G - Gift 428,022 650,266 192.59
2020-04-28 2020-03-18 4 ALLO Allogene Therapeutics, Inc.
Common Stock
G - Gift 428,022 650,266 192.59
2020-03-20 2020-03-18 4 ALLO Allogene Therapeutics, Inc.
Stock Option (Right to Buy)
A - Award 568,600 568,600
2020-03-18 2020-03-16 4 ALLO Allogene Therapeutics, Inc.
Common Stock
S - Sale -1,625 2,214,914 -0.07 20.06 -32,603 44,438,706
2020-03-18 2020-03-16 4 ALLO Allogene Therapeutics, Inc.
Common Stock
S - Sale -18,710 2,215,426 -0.84 19.24 -360,012 42,628,562
2020-03-11 2020-03-04 4 ALLO Allogene Therapeutics, Inc.
Common Stock
J - Other 9,391 2,234,136 0.42
2020-03-11 2020-03-04 4 ALLO Allogene Therapeutics, Inc.
Common Stock
J - Other X 9,402 1,191,910 0.80
2019-11-21 2019-11-19 4 ALLO Allogene Therapeutics, Inc.
Common Stock
J - Other 9,391 2,224,745 0.42
2019-11-21 2019-11-19 4 ALLO Allogene Therapeutics, Inc.
Common Stock
J - Other X 9,402 1,182,508 0.80
2019-10-29 2019-10-25 4 ALLO Allogene Therapeutics, Inc.
Common Stock
J - Other 9,391 2,215,354 0.43
2019-10-29 2019-10-25 4 ALLO Allogene Therapeutics, Inc.
Common Stock
J - Other X 9,402 1,173,106 0.81
2019-09-25 2019-09-23 4 ALLO Allogene Therapeutics, Inc.
Common Stock
J - Other 9,391 2,205,963 0.43
2019-09-25 2019-09-23 4 ALLO Allogene Therapeutics, Inc.
Common Stock
J - Other X 9,402 1,163,704 0.81
2019-09-09 2019-09-05 4 ALLO Allogene Therapeutics, Inc.
Common Stock
J - Other 9,391 2,195,469 0.43
2019-09-09 2019-09-05 4 ALLO Allogene Therapeutics, Inc.
Common Stock
J - Other X 9,402 1,154,302 0.82
2019-07-22 2019-07-18 4 ALLO Allogene Therapeutics, Inc.
Common Stock
J - Other 9,391 2,186,078 0.43
2019-07-22 2019-07-18 4 ALLO Allogene Therapeutics, Inc.
Common Stock
J - Other X 9,402 1,144,900 0.83
2019-07-12 2019-07-10 4 ALLO Allogene Therapeutics, Inc.
Common Stock
J - Other 6,388 2,176,687 0.29
2019-07-12 2019-06-18 4 ALLO Allogene Therapeutics, Inc.
Common Stock
J - Other X 10,154 1,135,498 0.90
2019-05-15 2019-05-13 4 ALLO Allogene Therapeutics, Inc.
Common Stock
J - Other X 11,753 1,125,344 1.06
2019-04-30 2019-04-26 4 ALLO Allogene Therapeutics, Inc.
Common Stock
J - Other X 11,753 1,113,591 1.07
2019-03-15 2019-03-13 4 ALLO Allogene Therapeutics, Inc.
Employee Stock Option (Right to Buy)
A - Award 292,700 292,700
2019-03-15 2019-03-13 4 ALLO Allogene Therapeutics, Inc.
Common Stock
A - Award 173,000 2,168,625 8.67
2018-10-17 2018-10-15 4 ALLO Allogene Therapeutics, Inc.
Series A Convertible Preferred Stock
C - Conversion -5,704 0 -100.00
2018-10-17 2018-10-15 4 ALLO Allogene Therapeutics, Inc.
Common Stock
C - Conversion 29,946 1,101,838 2.79
2018-10-17 2018-10-15 4 ALLO Allogene Therapeutics, Inc.
Common Stock
P - Purchase 40,000 1,995,625 2.05 18.00 720,000 35,921,250
2018-10-10 3 ALLO Allogene Therapeutics, Inc.
Common Stock
6,679,186
2018-10-10 3 ALLO Allogene Therapeutics, Inc.
Common Stock
5,795,453
2018-10-10 3 ALLO Allogene Therapeutics, Inc.
Common Stock
5,571,583
2018-10-10 3 ALLO Allogene Therapeutics, Inc.
Common Stock
5,571,583
2018-10-10 3 ALLO Allogene Therapeutics, Inc.
Common Stock
6,679,186
2018-10-10 3 ALLO Allogene Therapeutics, Inc.
Common Stock
5,795,453
2018-10-10 3 ALLO Allogene Therapeutics, Inc.
Common Stock
5,571,583
2018-10-10 3 ALLO Allogene Therapeutics, Inc.
Common Stock
5,571,583
2018-10-10 3 ALLO Allogene Therapeutics, Inc.
Common Stock
6,679,186
2018-10-10 3 ALLO Allogene Therapeutics, Inc.
Common Stock
5,795,453
2018-10-10 3 ALLO Allogene Therapeutics, Inc.
Common Stock
5,571,583
2018-10-10 3 ALLO Allogene Therapeutics, Inc.
Common Stock
5,571,583
2017-10-05 2017-10-03 4 KITE Kite Pharma, Inc.
Employee Stock Option (Right to Buy)
D - Sale to Issuer -90,600 0 -100.00
2017-10-05 2017-10-03 4 KITE Kite Pharma, Inc.
Employee Stock Option (Right to Buy)
D - Sale to Issuer -37,181 0 -100.00
2017-10-05 2017-10-03 4 KITE Kite Pharma, Inc.
Employee Stock Option (Right to Buy)
D - Sale to Issuer -28,919 0 -100.00 116.13 -3,358,363
2017-10-05 2017-10-03 4 KITE Kite Pharma, Inc.
Employee Stock Option (Right to Buy)
D - Sale to Issuer -23,437 0 -100.00
2017-10-05 2017-10-03 4 KITE Kite Pharma, Inc.
Employee Stock Option (Right to Buy)
D - Sale to Issuer -51,563 0 -100.00 128.04 -6,602,127
2017-10-05 2017-10-03 4 KITE Kite Pharma, Inc.
Employee Stock Option (Right to Buy)
D - Sale to Issuer -56,250 0 -100.00
2017-10-05 2017-10-03 4 KITE Kite Pharma, Inc.
Employee Stock Option (Right to Buy)
D - Sale to Issuer -116,750 0 -100.00 173.11 -20,210,592
2017-10-05 2017-10-03 4 KITE Kite Pharma, Inc.
Common Stock
D - Sale to Issuer -38,675 0 -100.00
2017-10-05 2017-10-03 4 KITE Kite Pharma, Inc.
Common Stock
U - Other -16,605 38,675 -30.04 180.00 -2,988,900 6,961,500
2017-10-05 2017-09-20 4 KITE Kite Pharma, Inc.
Common Stock
G - Gift -570 55,280 -1.02
2017-10-05 2017-09-13 4 KITE Kite Pharma, Inc.
Common Stock
G - Gift -157 55,850 -0.28
2017-10-05 2017-09-12 4 KITE Kite Pharma, Inc.
Common Stock
G - Gift -1,041 56,007 -1.82
2017-10-05 2017-09-11 4 KITE Kite Pharma, Inc.
Common Stock
G - Gift -375 57,048 -0.65
2017-09-27 2017-09-25 4 KITE Kite Pharma, Inc.
Common Stock
S - Sale -7,927 57,423 -12.13 179.66 -1,424,196 10,316,840
2017-09-27 2017-09-25 4 KITE Kite Pharma, Inc.
Common Stock
A - Award 15,000 65,350 29.79
2017-05-03 2017-05-01 4 KITE Kite Pharma, Inc.
Employee Stock Option (Right to Buy)
M - Exercise -20,000 123,000 -13.99
2017-05-03 2017-05-01 4 KITE Kite Pharma, Inc.
Common Stock
S - Sale X -300 50,165 -0.59 83.36 -25,008 4,181,754
2017-05-03 2017-05-01 4 KITE Kite Pharma, Inc.
Common Stock
S - Sale X -5,905 50,465 -10.48 82.60 -487,753 4,168,409
2017-05-03 2017-05-01 4 KITE Kite Pharma, Inc.
Common Stock
S - Sale X -13,795 56,370 -19.66 81.84 -1,128,983 4,613,321
2017-05-03 2017-05-01 4 KITE Kite Pharma, Inc.
Common Stock
M - Exercise 20,000 70,165 39.87 6.89 137,800 483,437
2017-04-04 2017-04-03 4 KITE Kite Pharma, Inc.
Employee Stock Option (Right to Buy)
M - Exercise -20,000 143,000 -12.27
2017-04-04 2017-04-03 4 KITE Kite Pharma, Inc.
Common Stock
S - Sale X -700 50,165 -1.38 83.66 -58,562 4,196,804
2017-04-04 2017-04-03 4 KITE Kite Pharma, Inc.
Common Stock
S - Sale X -8,697 50,865 -14.60 82.60 -718,372 4,201,449
2017-04-04 2017-04-03 4 KITE Kite Pharma, Inc.
Common Stock
S - Sale X -3,549 59,562 -5.62 82.00 -291,018 4,884,084
2017-04-04 2017-04-03 4 KITE Kite Pharma, Inc.
Common Stock
S - Sale X -2,424 63,111 -3.70 80.44 -194,987 5,076,649
2017-04-04 2017-04-03 4 KITE Kite Pharma, Inc.
Common Stock
S - Sale X -3,939 65,535 -5.67 79.63 -313,663 5,218,552
2017-04-04 2017-04-03 4 KITE Kite Pharma, Inc.
Common Stock
S - Sale X -691 69,474 -0.98 78.53 -54,264 5,455,793
2017-04-04 2017-04-03 4 KITE Kite Pharma, Inc.
Common Stock
M - Exercise 20,000 70,165 39.87 6.89 137,800 483,437
2017-03-02 2017-03-01 4 KITE Kite Pharma, Inc.
Employee Stock Option(Right to Buy)
M - Exercise -60,000 163,000 -26.91
2017-03-02 2017-03-01 4 KITE Kite Pharma, Inc.
Common Stock
S - Sale X -4,735 50,165 -8.62 79.71 -377,427 3,998,652
2017-03-02 2017-03-01 4 KITE Kite Pharma, Inc.
Common Stock
S - Sale X -55,265 54,900 -50.17 79.11 -4,372,014 4,343,139
2017-03-02 2017-03-01 4 KITE Kite Pharma, Inc.
Common Stock
M - Exercise 60,000 110,165 119.61 6.89 413,400 759,037
2016-12-27 2016-12-22 4 KITE Kite Pharma, Inc.
Employee Stock Option (Right to Buy)
A - Award 90,600 90,600
2016-12-27 2016-12-22 4 KITE Kite Pharma, Inc.
Common Stock
A - Award 24,800 49,923 98.71
2016-12-22 2016-12-20 4 KITE Kite Pharma, Inc.
Common Stock
S - Sale -1,788 25,123 -6.64 50.86 -90,938 1,277,756
2015-12-21 2015-12-17 4 KITE Kite Pharma, Inc.
Employee Stock Option (Right to Buy)
A - Award 66,100 66,100
2015-12-21 2015-12-17 4 KITE Kite Pharma, Inc.
Common Stock
A - Award 18,500 25,404 267.96
2015-11-12 2015-11-10 4 KITE Kite Pharma, Inc.
Employee Stock Option (Right to Buy)
M - Exercise -30,800 223,000 -12.14
2015-11-12 2015-11-10 4 KITE Kite Pharma, Inc.
Common Stock
S - Sale X -30,800 6,904 -81.69 80.02 -2,464,616 552,458
2015-11-12 2015-11-10 4 KITE Kite Pharma, Inc.
Common Stock
M - Exercise 30,800 37,704 446.12 6.89 212,212 259,781
2015-11-04 2015-11-02 4 KITE Kite Pharma, Inc.
Employee Stock Option (Right to Buy)
M - Exercise -7,700 253,800 -2.94
2015-11-04 2015-11-02 4 KITE Kite Pharma, Inc.
Common Stock
S - Sale X -3,923 6,904 -36.23 71.70 -281,279 495,017
2015-11-04 2015-11-02 4 KITE Kite Pharma, Inc.
Common Stock
S - Sale X -2,800 10,827 -20.55 70.96 -198,688 768,284
2015-11-04 2015-11-02 4 KITE Kite Pharma, Inc.
Common Stock
S - Sale X -500 13,627 -3.54 69.52 -34,760 947,349
2015-11-04 2015-11-02 4 KITE Kite Pharma, Inc.
Common Stock
S - Sale X -477 14,127 -3.27 68.27 -32,565 964,450
2015-11-04 2015-11-02 4 KITE Kite Pharma, Inc.
Common Stock
M - Exercise 7,700 14,604 111.53 6.89 53,053 100,622
2015-10-02 2015-10-01 4 KITE Kite Pharma, Inc.
Employee Stock Option (Right to Buy)
M - Exercise -7,700 261,500 -2.86
2015-10-02 2015-10-01 4 KITE Kite Pharma, Inc.
Common Stock
S - Sale X -7,700 6,904 -52.73 55.11 -424,347 380,479
2015-10-02 2015-10-01 4 KITE Kite Pharma, Inc.
Common Stock
M - Exercise 7,700 14,604 111.53 6.89 53,053 100,622
2015-09-08 2015-09-08 4 KITE Kite Pharma, Inc.
Employee Stock Option (Right to Buy)
M - Exercise -7,384 269,200 -2.67
2015-09-08 2015-09-08 4 KITE Kite Pharma, Inc.
Common Stock
S - Sale X -7,384 6,904 -51.68 55.00 -406,120 379,720
2015-09-08 2015-09-08 4 KITE Kite Pharma, Inc.
Common Stock
M - Exercise 7,384 14,288 106.95 6.89 50,876 98,444
2015-09-08 2015-09-03 4 KITE Kite Pharma, Inc.
Employee Stock Option (Right to Buy)
M - Exercise -316 276,584 -0.11
2015-09-08 2015-09-03 4 KITE Kite Pharma, Inc.
Common Stock
S - Sale X -316 6,904 -4.38 55.00 -17,380 379,720
2015-09-08 2015-09-03 4 KITE Kite Pharma, Inc.
Common Stock
M - Exercise 316 7,220 4.58 6.89 2,177 49,746
2015-08-04 2015-08-03 4 KITE Kite Pharma, Inc.
Employee Stock Option (Right to Buy)
M - Exercise -7,700 276,900 -2.71
2015-08-04 2015-08-03 4 KITE Kite Pharma, Inc.
Common Stock
S - Sale X -319 6,000 -5.05 73.87 -23,565 443,220
2015-08-04 2015-08-03 4 KITE Kite Pharma, Inc.
Common Stock
S - Sale X -2,205 6,319 -25.87 72.93 -160,811 460,845
2015-08-04 2015-08-03 4 KITE Kite Pharma, Inc.
Common Stock
S - Sale X -2,276 8,524 -21.07 72.29 -164,532 616,200
2015-08-04 2015-08-03 4 KITE Kite Pharma, Inc.
Common Stock
S - Sale X -2,900 10,800 -21.17 71.15 -206,335 768,420
2015-08-04 2015-08-03 4 KITE Kite Pharma, Inc.
Common Stock
M - Exercise 7,700 13,700 128.33 6.89 53,053 94,393
2015-07-02 2015-07-01 4 KITE Kite Pharma, Inc.
Employee Stock Option (Right to Buy)
M - Exercise -7,700 284,600 -2.63
2015-07-02 2015-07-01 4 KITE Kite Pharma, Inc.
Common Stock
S - Sale X -1,410 6,000 -19.03 62.97 -88,788 377,820
2015-07-02 2015-07-01 4 KITE Kite Pharma, Inc.
Common Stock
S - Sale X -2,896 7,410 -28.10 62.31 -180,450 461,717
2015-07-02 2015-07-01 4 KITE Kite Pharma, Inc.
Common Stock
S - Sale X -3,394 10,306 -24.77 61.15 -207,543 630,212
2015-07-02 2015-07-01 4 KITE Kite Pharma, Inc.
Common Stock
M - Exercise 7,700 13,700 128.33 6.89 53,053 94,393
2015-06-17 2015-06-15 4 KITE Kite Pharma, Inc.
Employee Stock Option (Right to Buy)
M - Exercise -7,700 292,300 -2.57
2015-06-17 2015-06-15 4 KITE Kite Pharma, Inc.
Common Stock
S - Sale X -2,541 6,000 -29.75 58.04 -147,480 348,240
2015-06-17 2015-06-15 4 KITE Kite Pharma, Inc.
Common Stock
S - Sale X -2,726 8,541 -24.19 56.93 -155,191 486,239
2015-06-17 2015-06-15 4 KITE Kite Pharma, Inc.
Common Stock
S - Sale X -2,433 11,267 -17.76 55.93 -136,078 630,163
2015-06-17 2015-06-15 4 KITE Kite Pharma, Inc.
Common Stock
M - Exercise 7,700 13,700 128.33 6.89 53,053 94,393
2015-06-17 2014-06-25 4 KITE Kite Pharma, Inc.
Common Stock
P - Purchase 4,000 6,000 200.00 17.00 68,000 102,000
2014-12-30 2014-12-24 4 KITE Kite Pharma, Inc.
Employee Stock Option (Right to Buy)
A - Award 75,000 75,000
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)